<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908777</url>
  </required_header>
  <id_info>
    <org_study_id>13-020</org_study_id>
    <nct_id>NCT01908777</nct_id>
  </id_info>
  <brief_title>A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the benefit of a chemotherapy drug called romidepsin in&#xD;
      patients with T Cell Non-Hodgkin Lymphoma (T NHL) who have undergone autologous&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim is to determine a preliminary estimate of the progression-free survival of&#xD;
      patients with T NHL who receive maintenance romidepsin at 2 years post-transplant for&#xD;
      patients transplanted in CR1 or PR1 with standard risk histologies.&#xD;
&#xD;
      Secondary aims include:&#xD;
&#xD;
        -  Determine PFS at 2 yrs for patients transplanted in ≥CR/PR2 or for patients with high&#xD;
           risk histologies.&#xD;
&#xD;
        -  Determine the toxicities associated with romidepsin following autologous transplantation&#xD;
&#xD;
        -  Determine the probability of OS at 2 years post transplant for all patients undergoing&#xD;
           transplant&#xD;
&#xD;
        -  Characterize the effect of romidepsin on immune recovery post HDT-ASCT&#xD;
&#xD;
        -  OS and PFS 1 year after Romidespin completion&#xD;
&#xD;
      Patients who receive romidepsin after transplant will be evaluable for the primary endpoint,&#xD;
      and will be counted towards the accrual total. Any patient who does not receive romidepsin&#xD;
      after transplant, regardless of reason, will be replaced. We will also accrue a second cohort&#xD;
      of 8 patients who are transplanted in &gt;CR/PR2 and for high risk histologies to be analyzed&#xD;
      for secondary endpoints only. This cohort will not be part of the primary endpoint and will&#xD;
      be analyzed for summary statistics only. Patients who receive romidepsin after transplant&#xD;
      will be counted towards the accrual total for Cohort 2. Any patient who does not receive&#xD;
      romidepsin after transplant, regardless of reason, will be replaced.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 16, 2013</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The progression-free survival of patients</measure>
    <time_frame>2 Years</time_frame>
    <description>The progression-free survival of patients with T NHL who receive maintenance romidepsin at 2 years post-transplant for patients transplanted in CR1 or PR1 with standard risk histologies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival for patients with high risk histologies</measure>
    <time_frame>2 Years</time_frame>
    <description>Determine PFS at 2 yrs for patients transplanted in ≥CR/PR2 or for patients with high risk histologies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>2 years</time_frame>
    <description>Determine the toxicities associated with romidepsin following autologous transplantation. Toxicities will be graded on a scale of 0 to 5 as described by the NCI- Common Terminology for Adverse Events (CTCAE), version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of OS at 2 years post transplant</measure>
    <time_frame>2 year post transplant</time_frame>
    <description>Determine the probability of OS at 2 years post transplant for all patients undergoing transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS 1 year after Romidespin completion</measure>
    <time_frame>1 year</time_frame>
    <description>OS 1 year after Romidespin completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS 1 year after Romidespin completion</measure>
    <time_frame>1 year</time_frame>
    <description>PFS 1 year after Romidespin completion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>T Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>high dose chemo w/asct + maintenance txt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose chemotherapy (Carmustine), VP-16 (etoposide, Vepesid®), Cytarabine (Ara-C), Melphalan (Alkeran)with autologous stem cell transplant followed by maintenance therapy with Romidepsin (Istodax)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin</intervention_name>
    <arm_group_label>high dose chemo w/asct + maintenance txt</arm_group_label>
    <other_name>Carmustine</other_name>
    <other_name>VP-16 (etoposide, Vepesid®)</other_name>
    <other_name>Cytarabine (Ara-C)</other_name>
    <other_name>Melphalan (Alkeran)</other_name>
    <other_name>Romidepsin (Istodax)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: Patients over age 16 who are deemed eligible for transplant by their treating&#xD;
             physician Disease status: CR or PR required. Remission status will be assessed at the&#xD;
             completion of induction chemotherapy and prior to enrollment on protocol.&#xD;
&#xD;
        Diagnosis: The following histologies will need to be confirmed at MSK or locally for&#xD;
        participating sites in order to be considered for HDT-ASCT and post-transplant maintenance&#xD;
        romidepsin:&#xD;
&#xD;
          -  PTCL&#xD;
&#xD;
          -  AITL&#xD;
&#xD;
          -  ALCL&#xD;
&#xD;
          -  EaTCL&#xD;
&#xD;
          -  Hepatosplenic Gamma Delta T cell lymphoma&#xD;
&#xD;
          -  Adult T-cell leukemia/lymphoma&#xD;
&#xD;
          -  Primary cutaneous gamma/delta T-cell lymphoma&#xD;
&#xD;
          -  Extranodal NK/T-cell lymphoma, nasal type&#xD;
&#xD;
          -  Primary cutaneous anaplastic large cell lymphoma&#xD;
&#xD;
          -  Subcutaneous panniculitis-like T-cell lymphoma&#xD;
&#xD;
          -  Mycosis fungoides/sezary syndrome Stem cell collection: A minimum of 2 x 106 CD34+&#xD;
             cells must have been collected&#xD;
&#xD;
        Laboratory test results within these ranges:&#xD;
&#xD;
          -  Total bilirubin &lt;= 1.5 x ULN&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) &lt;= 3 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis: progressive disease at transplant work-up&#xD;
&#xD;
          -  Prior therapy: prior autologous or allogeneic transplant&#xD;
&#xD;
          -  Active and uncontrolled infection at time of transplantation including active&#xD;
             infection with Aspergillus or other mold, or HIV infection&#xD;
&#xD;
          -  Inadequate performance status/organ function defined by DLCO &lt; 50% (adjusted for hgb),&#xD;
             cardiac function as defined below, KPS &lt; 60%.&#xD;
&#xD;
          -  Pregnant or breast feeding. For males and females of child-producing potential,&#xD;
             inability to use effective contraceptive methods during the study&#xD;
&#xD;
          -  Prior therapy with romidepsin&#xD;
&#xD;
          -  Central nervous system or meningeal involvement&#xD;
&#xD;
          -  Any known cardiac abnormalities such as:&#xD;
&#xD;
               -  Congenital long QT syndrome&#xD;
&#xD;
               -  QTc interval ≥ 500 milliseconds&#xD;
&#xD;
               -  Myocardial infarction within 6 months of transplantation. Subjects with a history&#xD;
                  of myocardial infarction between 6 and 12 months prior to transplant who are&#xD;
                  asymptomatic and have had a negative cardiac risk assessment (treadmill stress&#xD;
                  test, nuclear medicine stress test, or stress echocardiogram) since the event may&#xD;
                  participate&#xD;
&#xD;
               -  Other significant ECG abnormalities including 2nd degree atrio-ventricular (AV)&#xD;
                  block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50&#xD;
                  beats/min)&#xD;
&#xD;
               -  Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV (see&#xD;
                  Appendix 1) In any patient in whom there is doubt, the patient should have a&#xD;
                  stress imaging study and, if abnormal, angiography to define whether or not CAD&#xD;
                  is present&#xD;
&#xD;
               -  An ECG recorded at screening showing evidence of cardiac ischemia (ST depression&#xD;
                  of ≥2 mm, measured from isoelectric line to the ST segment). If in any doubt, the&#xD;
                  patient should have a stress imaging study and, if abnormal, angiography to&#xD;
                  define whether or not CAD is present&#xD;
&#xD;
               -  Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class&#xD;
                  II to IV definitions (see Appendix 2) and/or ejection fraction &lt;40% by MUGA scan&#xD;
                  or &lt;50% by echocardiogram and/or MRI&#xD;
&#xD;
               -  A known history of sustained ventricular tachycardia (VT), ventricular&#xD;
                  fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently&#xD;
                  addressed with an automatic implantable cardioverter defibrillator (AICD)&#xD;
&#xD;
               -  Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or&#xD;
                  other causes&#xD;
&#xD;
               -  Uncontrolled hypertension, defined as blood pressure (BP) of ≥160/95; patients&#xD;
                  who have a history of hypertension controlled by medication must be on a stable&#xD;
                  dose (for at least one month) and meet all other inclusion criteria&#xD;
&#xD;
               -  Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable&#xD;
                  doses of beta-blockers)&#xD;
&#xD;
               -  Patients taking drugs leading to significant QT prolongation within the specified&#xD;
                  wash out period (See Appendix 3: Medications That May Cause QTc Prolongation).&#xD;
&#xD;
               -  Concomitant use of CYP3A4 inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Horowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 17, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

